Abilify is an antipsychotic medicine. The active ingredient of the drug is Aripiprazole. The drug is prescribed for acute attacks of schizophrenia. It’s used for maintenance therapy and the elimination of acute manifestations of the pathology. The drug is effective in eliminating acute manic states in bipolar disorder. The neuroleptic is used to maintain the condition of patients with bipolar disorder type 1, with a history of manic or mixed episodes.
The drug acts on D2 dopamine and 5HT1 serotonin receptors. The active substance is an agonist of these receptors and acts on the reuptake of serotonin. The active substance is also an antagonist of 5HT2 serotonin receptors. Experiments have shown antagonism for dopaminergic hyperactivity and agonism for dopaminergic hypoactivity.
The average half-life is 75 hours. It accumulates in the tissues during therapy. The maximum concentration is reached 14 days after the start of administration. The active substance is quickly absorbed and accumulates in the blood plasma after 3-5 hours. The drug has high bioavailability, which is 85%. Food intake doesn’t affect absorption. 1% of the active substance is excreted unchanged in the urine, 18% in the feces.
Treatment begins with a dose of 10-15 mg once daily. To maintain the condition, 15 mg per day is prescribed. The drug has shown efficacy at a dosage of 10 to 30 mg. To treat manic episodes in bipolar disorder, 15 or 30 mg of the drug is used. The dosage can be changed depending on the condition after 24 hours. The drug is effective and improves the patient's condition when administered 15-30 mg for 3-12 weeks. A dosage of more than 30 mg is contraindicated due to the lack of clinical trials in this amount. If within 6 weeks of starting the drug there were no clinical manifestations of bipolar disorder and manic states, it should be thought that the therapy had the desired therapeutic effect. Patients should be evaluated periodically after therapy to avoid future manifestations of the disease.
For patients with kidney and liver disease, it is not necessary to change the dose. There is also no need to change the dosage when treating patients over 65 years of age, despite the lack of studies in this category of patients.
Clinical trials have reported cases of overdose when taking 1080 mg. Overdose has not resulted in serious consequences. Nausea, diarrhea, asthenia, vomiting, and diarrhea are more common when a large dose is taken. The patient may faint. A single intake of 450 mg can lead to changes in heart rhythm, tachycardia.
Overdose is treated symptomatically. It is important to keep the respiratory system functioning, provide enough oxygen. Cardiac activity should be monitored and an EKG should be performed. 50 grams of activated charcoal, taken no later than 60 minutes after taking the drug, can reduce the negative manifestations of overdose and avoid severe consequences.
There are no data on the effect of Abilify on pregnant women. Therefore, treatment with the drug is acceptable only if the benefit to the mother exceeds the possible risk to the fetus. During breastfeeding, treatment with the drug should be discontinued or breastfeeding should be stopped during therapy. There is no clear information about the absorption of the active ingredient into breast milk.
The drug is contraindicated for the treatment of patients under 18 years of age. It should not be used to treat children.
The cost of the drug depends on the dosage. The drug is produced in a dose of 10 mg, 15 mg, 30 mg. The dosage is selected depending on the condition of the patient after testing and examination by a doctor.
It is contraindicated to combine neuroleptics with alcohol. The occurrence of conditions dangerous to the body is possible.
During treatment with the drug, you should refrain from activities that require concentration. You should not drive a car.